INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
Scope & Guideline
Empowering healthcare through cutting-edge pharmacological studies.
Introduction
Aims and Scopes
- Clinical Pharmacokinetics and Pharmacodynamics:
The journal publishes research on the absorption, distribution, metabolism, and excretion (ADME) of drugs, as well as their pharmacological effects, highlighting studies that explore how various factors influence drug behavior in the body. - Therapeutic Drug Monitoring and Optimization:
There is a strong emphasis on studies that assess therapeutic drug monitoring (TDM) practices to optimize medication efficacy and minimize toxicity, particularly in vulnerable populations such as those with renal impairment or undergoing chemotherapy. - Pharmacovigilance and Drug Safety:
The journal includes articles on post-marketing surveillance, adverse drug reactions, and safety profiles of medications, underscoring the importance of pharmacovigilance in clinical practice. - Bioequivalence and Drug Formulation Studies:
Research on the bioequivalence of drug formulations and their implications for therapeutic efficacy is a core area, reflecting the journal's commitment to ensuring that generic and branded medications provide similar therapeutic outcomes. - Impact of Comorbidities on Pharmacotherapy:
The journal frequently publishes studies examining how comorbid conditions affect drug therapy, especially in populations with complex health needs, such as the elderly or those with chronic diseases. - Network Pharmacology and Traditional Medicine:
Emerging themes include the use of network pharmacology to understand drug interactions and the efficacy of traditional medicine, particularly in the context of integrative approaches to therapy.
Trending and Emerging
- COVID-19 Treatment and Drug Interactions:
A significant increase in research related to COVID-19, including drug interactions and treatment efficacy, underscores the pandemic's impact on clinical pharmacology and the urgency for effective therapeutic strategies. - Real-World Evidence and Patient-Centered Research:
There is a growing emphasis on real-world evidence studies that assess drug efficacy and safety in diverse patient populations, moving beyond controlled clinical trial settings to understand practical therapeutic outcomes. - Network Pharmacology and AI in Drug Research:
The utilization of network pharmacology and artificial intelligence to analyze drug interactions and therapeutic targets is gaining traction, indicating a modern approach to drug discovery and personalized medicine. - Polypharmacy and Drug-Drug Interactions:
Research focused on polypharmacy, particularly in geriatric populations, is on the rise, reflecting concerns about adverse drug interactions and the need for careful medication management. - Therapeutic Strategies for Chronic Diseases:
Emerging studies are increasingly addressing therapeutic strategies for managing chronic diseases, such as diabetes and cardiovascular conditions, highlighting the need for tailored pharmacotherapy in these populations.
Declining or Waning
- Basic Pharmacology Studies:
There appears to be a waning interest in basic pharmacological studies that do not directly translate into clinical applications, as the journal increasingly prioritizes research with immediate clinical relevance. - Non-Clinical Trial Research:
The publication of studies that focus solely on non-clinical trial methodologies or theoretical frameworks has decreased, indicating a preference for clinical trial data and real-world evidence. - Historical Drug Use Studies:
Research focusing on historical trends in drug use or retrospective analyses that do not incorporate current clinical guidelines or practices is less frequently featured, suggesting a pivot towards more contemporary, applicable research. - Single-Agent Pharmacotherapy:
There is a noticeable decline in studies examining the effects of single-agent therapies, as the journal increasingly highlights multi-drug regimens and combination therapies that reflect real-world clinical practice. - Pharmacogenomics:
Although pharmacogenomics remains important, there has been a relative decrease in the number of studies dedicated solely to genetic factors influencing drug response, as more integrated approaches are favored.
Similar Journals
BMC Pharmacology & Toxicology
Empowering discoveries in drug interactions and safety.Welcome to BMC Pharmacology & Toxicology, a premier open-access journal dedicated to advancing the fields of pharmacology and toxicology. Published by BMC since 2012, this esteemed journal offers a platform for researchers, professionals, and students to disseminate cutting-edge research and innovative findings that explore the intricate interactions between drugs and biological systems. With its robust Q2 ranking in both general medicine and pharmacology categories for 2023, BMC Pharmacology & Toxicology is recognized for its significant contributions to the academic community, reflected in its strategic positioning within the 61st and 49th percentiles in Scopus rankings for related disciplines. The journal's commitment to open access ensures that vital research is accessible to a global audience, fostering collaboration and informed discussions. We invite you to engage with the latest studies, reviews, and innovative methodologies that shape the future of pharmacological and toxicological sciences.
JOURNAL OF PHARMACY AND PHARMACOLOGY
Fostering collaboration in the realm of drug discovery.Journal of Pharmacy and Pharmacology, published by Oxford University Press, is a prestigious academic journal dedicated to the advancement of knowledge in the fields of pharmaceutical sciences and pharmacology. With a strong heritage dating back to 1949, this journal maintains a robust influence, as evidenced by its ranking in the second quartile (Q2) across both Pharmaceutical Science and Pharmacology categories for 2023. The journal is accessible without an open access option, ensuring traditional academic engagement and providing valuable insights for researchers and professionals. It boasts an impressive Scopus ranking, with a percentile positioning of 72nd in Pharmaceutical Science and 67th in Pharmacology. Aimed at fostering innovative research and facilitating the exchange of cutting-edge scientific knowledge, the Journal of Pharmacy and Pharmacology serves as an essential resource for scientists, students, and healthcare professionals committed to enhancing therapeutic outcomes and advancing pharmaceutical innovations.
DRUG DEVELOPMENT RESEARCH
Illuminating the path to novel therapeutics and safety assessments.DRUG DEVELOPMENT RESEARCH is a premier interdisciplinary journal published by Wiley, focusing on the latest advancements in drug discovery, pharmacology, and toxicology. With an ISSN of 0272-4391 and an E-ISSN of 1098-2299, this esteemed publication has been a cornerstone in the field since its inception in 1981 and continues to provide cutting-edge research until 2024. Its rigorous peer-review process and strategic placement in Q2 of the Drug Discovery category, as well as ranking #60 out of 157 in Scopus, underscore the journal's relevance and influence, boasting a respectable 62nd percentile ranking. While the journal does not currently offer open access, it remains a vital resource for researchers, professionals, and students seeking to expand their knowledge on the processes of drug development, identifying new therapeutic targets, and assessing the efficacy and safety of novel compounds. Situated in Hoboken, NJ, this journal stands at the forefront of pharmaceutical innovation, making significant contributions to the advancement of medical science.
BRITISH JOURNAL OF PHARMACOLOGY
Elevating research standards in the field of pharmacology.British Journal of Pharmacology is a premier, peer-reviewed journal published by Wiley, specializing in the dynamic field of pharmacology. With a robust impact factor, this journal ranks in the top quartile (Q1) for pharmacology according to the 2023 category rankings, emphasizing its significance and reputation among the global scientific community. As an essential resource for researchers, professionals, and students alike, the journal provides a platform for innovative research spanning foundational studies to clinical applications in pharmacology, toxicology, and pharmaceutics. Since its inception in 1966, the journal has consistently contributed to the advancement of pharmacological science, fostering a deeper understanding of drug action mechanisms and therapeutic advancements. Although primarily subscription-based, the British Journal of Pharmacology is committed to disseminating high-quality research that shapes the future of the field.
DRUGS IN R&D
Unlocking the potential of pharmacological sciences globally.DRUGS IN R&D is a premier open access journal dedicated to advancing the field of pharmacology and drug development. Published by Springer International Publishing AG, this journal has been a valuable resource for researchers and professionals since its inception in 1999, contributing critical insights into the pharmacological sciences. With an impressive Impact Factor reflecting its significance, DRUGS IN R&D ranks in the Q2 quartile for Pharmacology, according to 2023 metrics, and ranks #151 out of 313 in the field of pharmacology and toxicology on Scopus. This journal offers an open access format, ensuring high visibility and accessibility of research findings to a global audience, supporting the intrepid pursuit of knowledge in drug research and development. By facilitating comprehensive discussions and innovative research findings, DRUGS IN R&D plays a crucial role in shaping the future landscape of pharmacological studies and advancements.
International Journal of Pharmacology
Fostering Global Dialogue in Pharmacology and ToxicologyWelcome to the International Journal of Pharmacology, a key publication in the field of pharmacology, published by ASIAN NETWORK SCIENTIFIC INFORMATION (ANSINET). Since its inception in 2006, this journal has provided a vital platform for researchers and professionals to disseminate their findings and insights in pharmacology, toxicology, and pharmaceutics. Despite recent discontinuation in Scopus coverage, the journal's dedication to fostering scientific dialogue continues to attract contributions from esteemed scholars globally. With an **ISSN of 1811-7775** and **E-ISSN of 1812-5700**, the journal seeks to bridge the gap between laboratory research and clinical application, promoting a deeper understanding of drug actions and interactions. Although it operates under traditional access options, the relevance of its published studies to ongoing pharmacological research remains significant.
CLINICAL PHARMACOLOGY & THERAPEUTICS
Leading the way in pharmacology and therapeutics excellence.CLINICAL PHARMACOLOGY & THERAPEUTICS, published by WILEY, stands at the forefront of pharmacological research, serving as a pivotal resource for researchers, healthcare professionals, and students in the medical field. With its prestigious Q1 rating in both Pharmacology and Pharmacology (medical) categories, and ranking in the top 4% of journals in the field, it provides cutting-edge insights into drug therapy, pharmacokinetics, and innovative treatment strategies. The journal features a wide range of articles, from original research to comprehensive reviews, all aimed at advancing knowledge and clinical practice in pharmacology. With a publication history dating back to 1960 and continuing through 2024, its commitment to excellence is evident in its robust impact factor and high visibility in the academic community. For professionals striving to stay at the forefront of pharmacological advancements, CLINICAL PHARMACOLOGY & THERAPEUTICS remains an essential platform for disseminating and accessing vital research findings.
ANTI-CANCER DRUGS
Advancing the Frontiers of Cancer TherapeuticsANTI-CANCER DRUGS is a leading journal in the domain of cancer research and pharmacology, published by Lippincott Williams & Wilkins. With its inception dating back to 1990 and ongoing publication through 2024, this journal serves as a vital resource for researchers, clinicians, and students interested in the latest advancements and discoveries in cancer therapeutics. Although classified in the Q3 quartile across relevant categories such as Cancer Research and Oncology, its growing impact is evidenced by its competitive Scopus rankings, positioned within the 30th to 52nd percentiles across various disciplines. The journal remains committed to promoting innovative research that can translate into effective anti-cancer strategies, providing valuable insights into drug development and applications. While it does not currently offer open access, the journal continues to attract a sophisticated readership, making it an essential platform for disseminating significant findings in the ever-evolving field of oncology.
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS
Connecting Research and Practice for Optimal Animal Well-BeingJOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS is a crucial publication in the field of veterinary medicine, dedicated to advancing knowledge and practices related to pharmacology and therapeutic interventions in animals. Published by WILEY, this peer-reviewed journal has been a reliable source of innovative research since its inception in 1978, and it continues to play an integral role in shaping veterinary pharmacology through its commitment to high-quality scientific discourse. With an impact factor reflective of its robust academic standing, the journal is categorized in the Q3 quartile for Pharmacology and Q2 for Veterinary (miscellaneous) as of 2023, highlighting its relevance and significance within these domains. It is indexed in Scopus with commendable rankings, particularly in General Veterinary, where it ranks #45 out of 194, placing it in the 77th percentile. This journal not only offers a platform for original research articles but also caters to the dissemination of practical applications and reviews that are essential for veterinarians, researchers, and students alike in enhancing animal health and welfare. Although not an open-access publication, its contributions remain accessible to those engaged in the veterinary sciences through institutional subscriptions. The journal's enduring legacy and forward-looking approach make it a vital resource for anyone interested in veterinary therapeutics and pharmacology.
European Journal of Pharmacology
Unveiling groundbreaking research in pharmacokinetics and toxicology.The European Journal of Pharmacology, a prestigious publication by Elsevier, serves as a vital resource in the field of pharmacology, offering rich insights into drug development and therapeutic applications. Since its inception in 1967, this journal has evolved to encompass groundbreaking research, including pharmacokinetics, toxicology, and innovative pharmacological methodologies, making it an essential platform for researchers and professionals alike. With an impressive impact factor that places it in the Q1 category of pharmacological journals and a Scopus ranking of #49 out of 313, the journal is recognized in the 84th percentile within its category, solidifying its significance in the academic community. Although the journal is not open access, it continues to attract contributions from leading scientists worldwide, ensuring that cutting-edge findings are disseminated effectively. The European Journal of Pharmacology not only highlights advancements in drug discovery and clinical applications but also promotes interdisciplinary collaboration, ultimately contributing to the progress of healthcare globally.